XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.
S
S

Sanofi

පුවත්

Reuters - දින 1කට පෙර

Vaccine makers fall after Trump win

BUZZ-Vaccine makers fall after Trump win ** Shares of vaccine makers fall between 2% to 8% after Donald Trump is elected U.S. president for a second term ** Pfizer PFE.N down 2.4%, Moderna MRNA.O down 5%, Novavax NVAX.O down 7.7%, ** U.S.-listed shares of Sanofi SASY.PA , SNY.O and GSK GSK.L , GSK.N down 3.2% and 2.9% respectively ** Trump recently said he would let former presidential candidate and anti-vaccine advocate Robert F.
G
P
S
Reuters - දින 2කට පෙර

Sanofi-EMA Approves Dupixent For Eosinophilic Esophagitis In Children Aged One Year

BRIEF-Sanofi-EMA Approves Dupixent For Eosinophilic Esophagitis In Children Aged One Year Nov 6 (Reuters) - Sanofi SA SASY.PA : DUPIXENT APPROVED IN THE EU AS THE FIRST AND ONLY MEDICINE FOR YOUNG CHILDREN WITH EOSINOPHILIC ESOPHAGITIS EMA APPROVES DUPIXENT FOR EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED ONE YEAR PHASE 3 DATA SHOWS SIGNIFICANT REMISS
S
Reuters - දින 3කට පෙර

Sanofi Gets Marketing Authorization For Efluelda Vaccine For Next Influenza Season 2025/2026

BRIEF-Sanofi Gets Marketing Authorization For Efluelda Vaccine For Next Influenza Season 2025/2026 Nov 5 (Reuters) - Sanofi SA SASY.PA : SANOFI OBTAINS MARKETING AUTHORIZATION FOR EFLUELDA, ITS HIGH-DOSE TRIVALENT VACCINE, FOR THE NEXT INFLUENZA SEASON 2025/2026 AUTHORIZATION FROM ANSM Further company coverage: SASY.PA (Gdansk Newsroom)
S
Reuters - දින 3කට පෙර

Public funding for nature conservation stalls at COP16, eyes on private investment

UPDATE 1-Public funding for nature conservation stalls at COP16, eyes on private investment Rich countries did not respond to UN chief's demand for conservation donations Delegates hope revamping global financial system will generate cash for nature Countries reach deal on charging companies for genetic information use Updated to add comment from US State Department in paragraph 17 and AstraZeneca in paragraph 22 By Jake Spring CALI, Colombia, Nov 3 (Reuters) - Wealthy nations appeared to hit a
A
P
S
Reuters - දින 4කට පෙර

Public funding for nature conservation stalls at COP16, eyes on private investment

Public funding for nature conservation stalls at COP16, eyes on private investment Rich countries did not respond to U.N. chief's demand for conservation donations Delegates hope revamping global financial system will generate cash for nature Countries reach deal on charging companies for genetic information use By Jake Spring CALI, Colombia, Nov 3 (Reuters) - Wealthy nations appeared to hit a limit with how much they are willing to pay to conserve nature around the world, instead shifting their
P
S
Reuters - සති 1කට පෙර

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - සති 1කට පෙර

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - සති 1කට පෙර

Who in the US benefits from $35 insulin?

EXPLAINER-Who in the US benefits from $35 insulin? By Ahmed Aboulenein WASHINGTON, Oct 30 (Reuters) - Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a major accomplishment of the Biden administration, referring to a provision of the Inflation Reduction Act. Harris, the Democratic presidential candidate, and President Joe Biden describe the cap as one of their most important health policy wins, helping those who often could
S
Reuters - සති 2කට පෙර

European shares end week in the red as earnings disappoint

UPDATE 2-European shares end week in the red as earnings disappoint Mercedes car earnings plunge as China shuns luxury Electrolux slides on US woes, Chinese competition Signify shares soar as largely in-line Q3 provides relief Updated at 1603 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 25 (Reuters) - Europe's main stock index closed Friday's choppy session flat and notched weekly losses , as a handful of weak corporate earnings from auto-related companies such as Mercedes-Benz a
E
R
S
V
F
Reuters - සති 2කට පෙර

Sanofi shares seen up after Q3 beat

BUZZ-Sanofi shares seen up after Q3 beat ** Shares in Sanofi SASY.PA are seen up 1%-3.5% after the French pharma giant published Q3 results above expectations ** The group reported net sales for the quarter 6% above consensus at 13.44 billion euros ($14.53 billion), while business net income beat analyst expectations by 15% to 3.59 billion euros ** J.P.
S
Reuters - සති 2කට පෙර

Sanofi profit growth beats market view on early start of vaccine sales

REFILE-UPDATE 1-Sanofi profit growth beats market view on early start of vaccine sales Refiles with with name of analyst firm in paragraph 7 By Ludwig Burger Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
S
Reuters - සති 2කට පෙර

MARKETS ENTER THE EVENT STORM

LIVE MARKETS-MARKETS ENTER THE EYE OF RISK-EVENT STORM Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com MARKETS ENTER THE EYE OF RISK-EVENT STORM Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar .
A
A
G
M
S
T
J
U
E
F
U
G
Reuters - සති 2කට පෙර

Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus

BRIEF-Sanofi Q3 Business Operating Income Eur 4,607 Mln, Above Consensus Oct 25 (Reuters) - Sanofi SA SASY.PA : Q3 NET SALES EUR 13,438 MLN VS EUR 12,672 MLN IN VARA CONSENSUS Q3 BUSINESS EPS EUR 2.86 MLN VS EUR 2.49 MLN IN VARA CONSENSUS Q3 FREE CASH FLOW EUR 3,327 MLN, UP 79.5% YOY Q3 GROSS PROFIT EUR 10,074 MLN VS EUR 9,444 MLN IN VARA CONSENSUS
S
Reuters - සති 2කට පෙර

Sanofi CFO says won't be affected by Novo's Catalent deal

Sanofi CFO says won't be affected by Novo's Catalent deal FRANKFURT, Oct 25 (Reuters) - Sanofi's SASY.PA finance chief on Friday said the company won't be affected by Novo Nordisk's NOVOb.CO controlling shareholder's decision to acquire contract drug manufacturer Catalent CTLT.N , adding the deal made sense for its rival. "They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results .
S
Reuters - සති 2කට පෙර

Sanofi Q3 earnings beat market view, boosted by vaccine sales

Sanofi Q3 earnings beat market view, boosted by vaccine sales Oct 25 (Reuters) - French drug maker Sanofi SASY.PA on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines. Quarterly business operating income, excluding one-off items, rose by 14.4% to 4.6 billion euros ($5.0 billion), surpassing the average analyst estimate of 4 billion euros in a poll posted on the company's website.
S
Reuters - සති 2කට පෙර

Markets enter the eye of risk-event storm

MORNING BID EUROPE-Markets enter the eye of risk-event storm A look at the day ahead in European and global markets from Kevin Buckland Yields are mercifully lower as the week draws to a close, removing some of the angst that has weighed on equities and allowing the beaten-down yen and euro to regain some composure against the dollar . But this relative calm feels like the eye of the storm as risk events swirl on the horizon next week: mega-cap earnings from five of the "Magnificent 7"; a highly
A
A
E
M
S
T
U
J
U
U
U
Reuters - සති 2කට පෙර

Dealmakers expect bigger European private equity buyouts and more of them

ANALYSIS- Dealmakers expect bigger European private equity buyouts and more of them Number of $5bn plus deals more than doubled in year to date Uninvested cash has piled up Private equity investors press for returns through asset sales By Amy-Jo Crowley, Andres Gonzalez, Mathieu Rosemain and Anousha Sakoui LONDON, Oct 22 (Reuters) - Buyout fund CD&R's keenly awaited 16 billion euro ($17.36 billion) deal to take control of Sanofi's consumer health unit, could herald an upsurge in big private equi
S
Reuters - සති 2කට පෙර

British Business - Oct. 22

PRESS DIGEST-British Business - Oct. 22 Oct 21 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British engineering company Ricardo RCDO.L said it is divesting its defence business as part of a five-year strategic shift to become an "engineering consultancy in environmental and energy transition".
M
O
P
S
V
V
Reuters - සති 3කට පෙර

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Secureworks, Atlantic Union Bankshares, Catalent, Viad Corp Updates: EQT AB, DNB, CITIC Ltd Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Cybersecurity firm Sophos, which is backed by private equity firm Thoma Bravo, said it will acquire Secureworks SCWX.O for $859 million in an all-cash deal to strengthen its cybersecurity offering for small, mid and enterprise customers.
M
S
U
D
Reuters - සති 3කට පෙර

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** China's state-owned CITIC Ltd 0267.HK has agreed to sell its 19.23% stake in Fast Food Holdings, the company behind McDonald's China and Hong Kong operations, to Trustar Fast Food Holdings for $430.3 million.
M
S
U

තත්ත්වයන්

ජනප්‍රිය වත්කම්

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.